The pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in human volunteers and patients with reversible obstructive airways disease
about
The effect of physiological manoeuvres on the absorption of inhaled nedocromil sodium.Deep inspiration increases the absorption of inhaled sodium cromoglycateThe effect of respiratory manoeuvres and pharmacological agents on the pharmacokinetics of nedocromil sodium after inhalationFlip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug developmentPharmacometric Models for Characterizing the Pharmacokinetics of Orally Inhaled Drugs.Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCSMetabolic considerations of drugs in the treatment of allergic diseases.A clinical overview of Tilarin.Nedocromil sodium 2% ophthalmic solution (Tilavist(TM)) A new topical treatment for ocular allergic inflammation.Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation.Nedocromil sodium.Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients.The acceptability, safety and efficacy of nedocromil sodium in long-term clinical use in patients with perennial asthma.
P2860
Q34346182-7F4747BC-0FD9-4860-93C5-3A6FF5780F3CQ34397367-A92D9080-5539-415E-A17B-B91822F48508Q34402996-E26AD0E2-E7B9-4AD3-AB8D-69546F1CC833Q35153417-DF062F92-42B7-400C-8509-C6CF4C567269Q35768436-AB38B8CE-2C56-4D0A-B7BA-18C938C4B98EQ35952140-F0BC8E96-989F-4C6B-80BF-BCA8E59B8069Q38125525-46ADDE86-E3E5-4C00-A1C1-A0BCE089A679Q39469550-D6D6BE38-1FA5-4E70-9FDB-DE154A369A40Q39496206-B7C883FC-46A6-4FE5-B751-B3C8E9850DD7Q39794883-8BBB5EB5-C0C1-42B6-983B-21924D7FAF4CQ40856631-286C1E9B-C558-4AC6-ABFA-9EA8859B1635Q43824939-811847DF-C31B-4F0E-9913-8BA62A659AA0Q54122168-2B0982D0-F3AA-4814-AB18-E4E935CCF2DA
P2860
The pharmacokinetics of nedocromil sodium, a new drug for the treatment of reversible obstructive airways disease, in human volunteers and patients with reversible obstructive airways disease
description
1987 nî lūn-bûn
@nan
1987 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
The pharmacokinetics of nedocr ...... le obstructive airways disease
@ast
The pharmacokinetics of nedocr ...... le obstructive airways disease
@en
The pharmacokinetics of nedocr ...... le obstructive airways disease
@nl
type
label
The pharmacokinetics of nedocr ...... le obstructive airways disease
@ast
The pharmacokinetics of nedocr ...... le obstructive airways disease
@en
The pharmacokinetics of nedocr ...... le obstructive airways disease
@nl
prefLabel
The pharmacokinetics of nedocr ...... le obstructive airways disease
@ast
The pharmacokinetics of nedocr ...... le obstructive airways disease
@en
The pharmacokinetics of nedocr ...... le obstructive airways disease
@nl
P2093
P2860
P1476
The pharmacokinetics of nedocr ...... le obstructive airways disease
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1987.TB03203.X
P407
P577
1987-10-01T00:00:00Z